INCB13739 is developed as a new treatment for type 2 diabetes. It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme...
- Mechanism
- Curator reviewed
INCB13739 is an inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes. INCB13739 completely inhibits the production of intra-adipose and intra-hepatic cortisol by 11beta-HSD1, while maintaining normal systemic cortisol levels, which are essential for immune function and response to stress.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2 and diabetes prevention.Curator reviewed
- Code names
- INCB13739
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with INCB13739, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account